The 20-F confirms the company's cash burn rate has nearly doubled YoY, which accelerates the need for a dilutive capital raise to fund the planned Phase 3 trial. Monitor for equity offering announcements (e.g., S-3 or ATM filings) and any updates on the Phase 3 trial initiation timeline, which the company targeted to begin by end of calendar 2026.
Price Chart
Executive Summary
Alterity Therapeutics filed its annual report (20-F) for the fiscal year ended June 30, 2026, reporting an operating loss of $23.4 million (up from $12.1 million in FY2025) and an operating cash outflow of $22.5 million. The company highlighted positive FDA feedback and alignment on key elements of a registrational Phase 3 program for its lead candidate ATH434 in Multiple System Atrophy (MSA), but also disclosed it is a PFIC for U.S. tax purposes and faces substantial doubt about its ability to continue as a going concern without further capital raises. The filing is largely a routine annual update with no new material financial or operational catalysts beyond what was previously disclosed in 6-K filings.
Key Facts
- Operating loss of $23.4 million for FY2026, compared to $12.1 million for FY2025.
- Operating cash outflow of $22.5 million for FY2026, compared to $11.5 million for FY2025.
- Positive FDA feedback and alignment on key elements of the registrational Phase 3 program for ATH434 in MSA, disclosed in June 2026.
- Company states it will require substantial additional funding to support Phase 3 development of ATH434.
- Company believes it is a PFIC for the taxable year ended June 30, 2026 for some U.S. investors.
- 217,508,862 ordinary shares outstanding as of June 30, 2026.
- No revenue reported; company is a pre-revenue clinical-stage biotech.
Financial Impact
Operating loss increased by $11.3 million YoY to $23.4 million; cash burn increased by $11.0 million to $22.5 million.
Risk Factors
- Substantial additional capital required for Phase 3 development, likely leading to shareholder dilution.
- Pre-revenue clinical-stage company with no approved products and a history of operating losses.
- PFIC status may deter U.S. institutional investors and create adverse tax consequences for U.S. holders.
- Reliance on single lead candidate ATH434; any clinical or regulatory setback would be material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001437749-26-029135 |
| Document: 0001437749-26-029135-index.html | 0001437749-26-029135 |
| Document: 0001437749-26-029135.txt | 0001437749-26-029135 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.14 (−2.39%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.14 (+2.39%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.14 (+2.39%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.14 (−10.46%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.14 (−10.46%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.14 (−11.93%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.14 (−31.41%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.14 (−33.54%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.14 (−33.54%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.14 (−41.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers